Literature DB >> 15959768

One-milliliter wet-digestion for inductively coupled plasma mass spectrometry (ICP-MS): determination of platinum-DNA adducts in cells treated with platinum(II) complexes.

Kanae Yamada1, Naoyuki Kato, Akimitsu Takagi, Minoru Koi, Hiromichi Hemmi.   

Abstract

Platinum (Pt)-DNA adducts formed by the anti-tumor agent cisplatin are recognized by the DNA mismatch repair (MMR) system. To investigate the involvement of MMR proteins including hMLH1 in the removal of these adducts, we developed a mL-scale wet-digestion method for inductively coupled plasma mass spectrometry (ICP-MS). The detection limit was 0.01 ng mL(-1) Pt, which corresponded to 2 pg Pt/microg DNA when 10 microg of DNA was used. The mean relative errors were 5.4% or better for a dynamic range of 0.01-10 ng mL(-1) Pt. DNA (approximately 500 microg) had no matrix effect. To improve the accuracy, DNA preparations were treated with ribonuclease and the apparent reduction in the concentration of Pt was corrected using cellular DNA levels, which were determined with Hoechst 33258. No significant differences were observed, in terms of the formation of Pt-DNA adducts or their removal over 6 h, between hMLH1-deficient HCT116 cells, a human colorectal cancer cell line, and hMLH1-complemented HCT116+ch3 cells (n=5; P>0.05), indicating that the hMLH1-dependent DNA repair systems contribute to neither the formation nor the removal of the adducts at detectable levels. In addition, approximately 19% of the adducts were removed within 6 h in both cell lines. A time course analysis (~24 h) suggested that the removal of cisplatin-generated Pt-DNA adducts follows first-order kinetics (t(1/2)=32 h). The amount of Pt-DNA adduct formed by oxaliplatin in 1 h was 56% (ratio of means) of that generated by an equimolar concentration of cisplatin in HCT116. The proposed procedure could be useful for determining Pt-DNA adducts formed by Pt(II) complexes.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15959768     DOI: 10.1007/s00216-005-3339-5

Source DB:  PubMed          Journal:  Anal Bioanal Chem        ISSN: 1618-2642            Impact factor:   4.142


  5 in total

1.  Analysis of the DNA damage produced by a platinum-acridine antitumor agent and its effects in NCI-H460 lung cancer cells.

Authors:  Xin Qiao; Alexandra E Zeitany; Marcus W Wright; Amal S Essader; Keith E Levine; Gregory L Kucera; Ulrich Bierbach
Journal:  Metallomics       Date:  2012-03-29       Impact factor: 4.526

2.  Encapsulation, controlled release, and antitumor efficacy of cisplatin delivered in liposomes composed of sterol-modified phospholipids.

Authors:  Heidi M Kieler-Ferguson; Darren Chan; Jonathan Sockolosky; Lydia Finney; Evan Maxey; Stefan Vogt; Francis C Szoka
Journal:  Eur J Pharm Sci       Date:  2017-03-03       Impact factor: 4.384

Review 3.  Personalized medicine for targeted and platinum-based chemotherapy of lung and bladder cancer.

Authors:  George D Cimino; Chong-xian Pan; Paul T Henderson
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

4.  Oxaliplatin and its enantiomer induce different condensation dynamics of single DNA molecules.

Authors:  Hong-Yan Zhang; Yu-Ru Liu; Chao Ji; Wei Li; Shuo-Xing Dou; Ping Xie; Wei-Chi Wang; Ling-Yun Zhang; Peng-Ye Wang
Journal:  PLoS One       Date:  2013-08-12       Impact factor: 3.240

5.  DNA Adducts from Anticancer Drugs as Candidate Predictive Markers for Precision Medicine.

Authors:  Alessia Stornetta; Maike Zimmermann; George D Cimino; Paul T Henderson; Shana J Sturla
Journal:  Chem Res Toxicol       Date:  2017-01-03       Impact factor: 3.739

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.